Authors’ commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy

M. Y. Frolov

For citations:

Frolov M.Y. Authors’ commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy. Cancer Urology. 2017;13(2):128-130. (In Russ.)

Views PDF (Rus): 176

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Cancer Urology

For citations:

Cookies policy